Minerva Neurosciences Q1 2026 Earnings EPS Misses Street Estimates Stock Gains on Pipeline Optimism TERN Q4 2025 Earnings NarrowerThanExpected Loss Highlights Cost Discipline Amid PreRevenue Stage XORTX Therapeutics Q1 2024 Earnings Steep EPS Miss Highlights PreRevenue Biotech Hurdles AEBI Q1 2026 Earnings EPS Misses Estimates as Profitability Challenges Persist BLTE Q4 2025 Earnings WiderthanExpected Loss as PreRevenue Biotech Remains Focused on Clinical Development Jim Cramer Tech Investing Landscape Undergoes Permanent Shift Toward Semiconductor and AI Infrastructure TRMB Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency